About this trial
This study is part of the performance evaluation to support the conformity assessment procedure for the use of fingerstick whole blood samples with Abbott's Panbio™ HCV Self Test device, as performed by lay users. The study will be conducted in accordance with the Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council and, to provide data to demonstrate the product is safe and effective for its intended use.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participant is aged 18 or over
Participant agrees to all aspects of the study and is able and willing to provide informed consent / assent with parental consent.
Disqualifiers
Participant has already participated in this study on a previous occasion.
Participant is deemed unfit for the study by the Investigator.
Participant has a condition deemed unfit by the Investigator to safely perform or receive the test.
Participant is a practising health-care professional or laboratory scientist / technician or has prior medical or laboratory training or experience
Trial population
Participants with any known or suspected anti-HCV status may be enrolled.
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Panbio™ HCV Self Test
Diagnostic testRapid diagnostic test (self-test and professional) plus laboratory reference tests
Treatment groups
Trial outcomes
Primary outcomes
Lay user / professional user test result concordance
To assess the concordance between the Panbio™ HCV Self Test, as performed by lay users based on self-collected finger-stick samples, and the Panbio™ HCV Self Test performed by a trained health care worker, who also will collect the finger-stick sample required for the test and perform the test.
Lay user / laboratory test result concordance
To establish clinical performance (concordance with the reference test) for the Panbio™ HCV Self Test, as performed by lay users using finger-stick whole blood samples, when compared to reference testing using venous plasma samples.
Secondary outcomes
Labelling comprehension evaluation
To evaluate user experience and lay user participants' understanding of the test through a questionnaire. The participant questionnaire includes questions which are intended to evaluate the lay user's understanding of the Quick Reference Guide / Instructions for Use. Most questions have a Yes / No answer option, with free text possible. Some questions require a free text answer.
Results interpretation evaluation
To evaluate the lay users' understanding of static test results (mock devices).
Usability evaluation - lay user experience
To assess the usability of the Panbio™ HCV Self Test, as performed by lay users, based on a participant questionnaire evaluation by the lay user participant. The participant questionnaire includes questions to assess the lay users' experience when performing the test. Most questions have a Yes / No answer option, with free text possible. Some questions require a free text answer.
Usability evaluation - Self-test observer records
To assess the usability of the Panbio™ HCV Self Test, as performed by lay users based on a questionnaire evaluation by the study staff observer. In the observer questionnaire, particular attention will be paid to compliance regarding factors considered critical for the test, such as reading the IFU/ QRG and applying the correct test volume. The observer questionnaire is not reporting scores on a scale, but is recording observations regarding how the users complete each step. For each step, a question is asked whether the user conducted a certain procedure, and a Yes / No answer is requested, with Monitor Notes when applicable.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: